Clinical trial · Observational
Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)
Palliation in Gynae-oncology: Patients Expectations and Assessment of Care
NCT05142150CI-TRIAL-00081161PEACErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall aim is to assess the feasibility and acceptability of collecting data on the patients and carers perception of care as well as to prospectively monitor end of life care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynaecological Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patient
- description
- Patient satisfaction with end of life care. Questionnaire to be completed at baseline and every 8 week.
- interventionNames
- Other: Questionaire
- label
- Carer
- description
- Carer satisfaction with care leading up to the time of death and the quality of the patient's death. Questionnaire to be completed at baseline and every 8 weeks,and 5-7 weeks after patient deceased.
- interventionNames
- Other: Questionaire
Primary outcomes (1)
- measure
- Number of patients who complete scheduled assessments with Canadian Health Care Evaluation Project (CANHELP) instrument, CANHELP Lite Individualised version
- timeFrame
- Within 42 days before their death
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: A patient will be eligible for inclusion only if all of the following criteria are fulfilled: 1. Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician\*. Potential patient groups include, but are not limited to, those with platinum-resistant/refractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic/recurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade/undifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc. 2. Patients may be on active cancer treatment, about to commence active cancer treatment or under observation/palliative care. 3. Age ≥ 18 years 4. Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator). Exclusion Criteria: A patient will not be eligible for inclusion if any of the following criteria are fulfilled: 1. Unable to be comply with the protocol. 2. A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc. 3. Participation in another clinical trial. A patient will be asked to appoint a carer. Inclusion criteria carer: 1. Age ≥ 18 years 2. A relative or close friend who is actively supporting the patient in her illness 3. Able (both physically and cognitively) to complete questionnaires independently in languages that are available in this study (i.e. without assistance from hospital translator). Exclusion criteria carer A carer will not be eligible for inclusion if any of the following criteria are fulfilled: 1. Unable to be comply with the protocol 2. A medical or psychological condition that limits the carer´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.
References
Publications (0)
Data not yet available
No reference posted for this study.